Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Pharmagreen Biotech Inc. operates as a micro-cap specialty pharmaceutical company with minimal revenue generation ($0.0B TTM) and severe cash burn characteristics. The company exhibits extreme operational inefficiency with -7273% operating margin and -29443% net margin, indicating a pre-revenue or distressed development-stage entity. The 100% six-month return suggests speculative trading activity rather than fundamental value creation.
As a development-stage specialty pharmaceutical entity with effectively zero revenue, PHBI appears to be in pre-commercialization phase. The 50.9% gross margin on negligible revenue suggests limited product sales or cost allocation anomalies. The company likely relies on equity financing given negative operating cash flow and 0.04 current ratio, indicating severe liquidity constraints. No identifiable competitive advantages or pricing power at this stage of development.
Clinical trial announcements or regulatory milestone updates (primary driver for pre-revenue biotech)
Financing events and equity dilution concerns given 0.04 current ratio and negative cash flow
Partnership or licensing deal speculation with established pharmaceutical companies
Speculative trading volume and retail investor sentiment (evidenced by 100% six-month spike)
FDA regulatory pathway developments or expedited review designations
Clinical trial failure risk with binary outcomes that could render equity worthless (standard biotech development risk)
Regulatory approval uncertainty with FDA pathway complications or extended review timelines
Technological obsolescence if competing therapies achieve faster commercialization or superior efficacy profiles
Healthcare reimbursement policy changes affecting future commercial viability of pipeline products
Well-capitalized pharmaceutical competitors with established regulatory expertise and faster development timelines
Generic drug manufacturers potentially targeting same therapeutic areas with lower-cost alternatives
Inability to attract partnership interest from major pharmaceutical companies due to limited differentiation
Imminent liquidity crisis indicated by 0.04 current ratio and negative operating cash flow requiring immediate equity raise
Severe equity dilution risk to existing shareholders from necessary financing at distressed valuations
Negative shareholder equity (-0.5x price/book) suggesting accumulated deficits exceed asset base
Going concern risk if unable to secure financing within next 1-2 quarters given current burn rate
moderate - Pre-revenue biotech companies show indirect GDP sensitivity through venture capital availability and risk appetite. Economic downturns reduce speculative capital flows into development-stage companies, while expansions increase funding availability. However, pharmaceutical demand itself remains relatively GDP-insensitive, creating mixed cyclical exposure.
Rising interest rates negatively impact PHBI through multiple channels: (1) higher discount rates compress NPV of distant future cash flows from potential products, (2) reduced risk appetite shifts capital away from speculative micro-caps toward safer yield alternatives, (3) increased cost of capital for future financing rounds given likely equity dependence. The negative price/book ratio (-0.5x) suggests severe valuation pressure already present.
High exposure to equity market conditions rather than traditional credit markets. With -0.14 debt/equity ratio (negative equity) and 0.04 current ratio, the company lacks access to conventional credit facilities. Survival depends entirely on equity financing availability, making it highly sensitive to risk-on/risk-off market dynamics and biotech sector sentiment rather than credit spreads.
momentum/speculative - The 100% six-month return combined with 5.9% one-year return indicates extreme volatility driven by speculative retail traders rather than fundamental investors. The near-zero market cap, negative cash flow, and binary clinical outcomes attract high-risk tolerance speculators seeking lottery-ticket exposure. Institutional ownership likely minimal given liquidity constraints and balance sheet distress.
high - Micro-cap pre-revenue biotech stocks exhibit extreme volatility with typical beta >2.0. Binary clinical events create 50%+ single-day moves. The 100% six-month spike followed by reversion demonstrates speculative boom-bust patterns. Illiquidity amplifies price swings on minimal volume.
